Neuland Laboratories Ltd
Neuland Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management. Neuland targets an 18% to 20% CAGR over a 5-year horizon, described as aspirational rather than linear growth (Saharsh Davuluri, page 15).
From Neuland Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management.
- FY26 revenue reached INR 2,000 crores, up from INR 1,500+ crores in FY24, reflecting meaningful growth after a volatile FY25.
- Growth is expected to remain lumpy and volatile in the short to medium term due to the nature of the business and newer high-value molecules.
- Long-term growth is anchored by commercial and near-commercial molecules, with a strong pipeline and increasing engagement with big pharma.
- Investments in large-scale peptide commercial facilities and an upgraded R&D center aim to expand capacity and technical capabilities, supporting sustainable growth.
2 more points from Neuland Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Neuland Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Neuland is in a phase of longer capital deployment cycles focused on long-term growth rather than tactical investments (Page 11).
- Capex outflow for FY26 was INR 397.1 crores, executed with discipline aligned with strategic priorities emphasizing returns and capability building (Page 4).
- Investments include building a large-scale peptide commercial facility to expand capabilities in peptide APIs and fragments (Page 5).
- New R&D center for supporting complex programs, enhancing scientific depth, collaboration, and scale from early development to commercialization (Page 5).
- Capital allocation mindset is evolving to support larger annual capex (hundreds to INR 1,000 crores) for scaling production and engaging big pharma clients (Page 11).
2 more points from Neuland Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Neuland Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Management indicates "visibility for projects" especially for the new peptide facility expected to be operational by July, suggesting a healthy pipeline.
- Early-stage projects for the peptide facility are near commercial, with project visibility but not yet firm contracts.
- The business development focus is on attracting high-quality, sustainable growth opportunities and larger projects.
2 more points from Neuland Laboratories Ltd's call on order book
Create a free account to keep reading this call
Neuland Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Neuland Labs.'s management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Guj. Themis Bio. (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Neuland Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Neuland Laboratories Ltd Q4 FY26 results?
Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management. Neuland targets an 18% to 20% CAGR over a 5-year horizon, described as aspirational rather than linear growth (Saharsh Davuluri, page 15).
What is Neuland Laboratories Ltd share price analysis?
Neuland Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 51.4 with a market cap of ₹25,603 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neuland Laboratories Ltd planning capital expenditure?
Neuland is in a phase of longer capital deployment cycles focused on long-term growth rather than tactical investments (Page 11).
Keep Neuland Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.